Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

442 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatoid adenocarcinoma of the colon: what should we target?
Cappetta A, Bergamo F, Mescoli C, Lonardi S, Rugge M, Zagonel V. Cappetta A, et al. Among authors: zagonel v. Pathol Oncol Res. 2012 Jan;18(1):93-6. doi: 10.1007/s12253-011-9424-5. Epub 2011 Jun 12. Pathol Oncol Res. 2012. PMID: 21667305 Free article.
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E. Loupakis F, et al. Among authors: zagonel v. Cancer. 2012 Mar 15;118(6):1523-32. doi: 10.1002/cncr.26460. Epub 2011 Aug 25. Cancer. 2012. PMID: 22009364 Free article.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients.
Brunello A, Fontana A, Zafferri V, Panza F, Fiduccia P, Basso U, Copetti M, Lonardi S, Roma A, Falci C, Monfardini S, Cella A, Pilotto A, Zagonel V. Brunello A, et al. Among authors: zagonel v. J Cancer Res Clin Oncol. 2016 May;142(5):1069-77. doi: 10.1007/s00432-015-2088-x. Epub 2016 Jan 12. J Cancer Res Clin Oncol. 2016. PMID: 26758276 Free PMC article.
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Sartore-Bianchi A, et al. Among authors: zagonel v. Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Lancet Oncol. 2016. PMID: 27108243 Free article. Clinical Trial.
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest. Cremolini C, et al. Among authors: zagonel v. BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z. BMC Cancer. 2017. PMID: 28599628 Free PMC article. Clinical Trial.
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients.
Cascinu S, Rosati G, Nasti G, Lonardi S, Zaniboni A, Marchetti P, Leone F, Bilancia D, Iaffaioli RV, Zagonel V, Giordano M, Corsi DC, Ferraú F, Labianca R, Ronzoni M, Scartozzi M, Galli F; GISCAD investigators. Cascinu S, et al. Among authors: zagonel v. Eur J Cancer. 2017 Sep;83:106-115. doi: 10.1016/j.ejca.2017.06.029. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735067 Clinical Trial.
442 results